Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.
Main Authors: | , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
2016
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1516-84842016000200099 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1516-848420160002000992016-06-29Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disordersFonseca-Hial,Ana Marcela RojasParisio,KatyaOliveira,Jose Salvador Rodrigues Hematopoietic stem cell transplant Indolent lymphoproliferative disorder Reduced intensity conditioning Graft-versus-lymphoma Allogeneic ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.38 n.2 20162016-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099en10.1016/j.bjhh.2016.02.006 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Fonseca-Hial,Ana Marcela Rojas Parisio,Katya Oliveira,Jose Salvador Rodrigues |
spellingShingle |
Fonseca-Hial,Ana Marcela Rojas Parisio,Katya Oliveira,Jose Salvador Rodrigues Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
author_facet |
Fonseca-Hial,Ana Marcela Rojas Parisio,Katya Oliveira,Jose Salvador Rodrigues |
author_sort |
Fonseca-Hial,Ana Marcela Rojas |
title |
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_short |
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_full |
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_fullStr |
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_full_unstemmed |
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
title_sort |
allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders |
description |
ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy. |
publisher |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publishDate |
2016 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099 |
work_keys_str_mv |
AT fonsecahialanamarcelarojas allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders AT parisiokatya allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders AT oliveirajosesalvadorrodrigues allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders |
_version_ |
1756423602696093696 |